Approximately 50–60% of melanomas bearing mutations in the protein kinase BRAF are eligible for treatment with BRAF and MEK inhibitors, targeting mutant forms of BRAF (BRAFi) and MEK (MEKi) in the mitogen-activated protein kinase (MAPK) pathway to block cancer cell survival signals [4]. This evidence concerns the gene MAP2K7 and cancer.